Search
Casimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigational[A218186, L32118] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit drastically reduced metabolic degradation compared to traditional synthetic oligonucleotides. … on further verification in confirmatory trials.
Categories: Compounds used in a research, industrial, or household settingTetrachlorodecaoxide
go.drugbank.com/drugs/DB05389ApprovedThe Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer. … The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the
Categories: Compounds used in a research, industrial, or household settingMidazolam
go.drugbank.com/drugs/DB00683ApprovedIllicitInvestigational[L45098] In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. … [L45098] In May 2019, the nasal spray of midazolam was approved for the acute treatment of distinctive intermittent, stereotypic seizure episodes in patients 12 years of age and older.
Products: N/a, Midazolam in Sodium ChlorideTafluprost
go.drugbank.com/drugs/DB08819ApprovedTafluprost was approved for use in the U.S. on February 10, 2012. … A prostaglandin analogue ester prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.
Mixtures: TAPCOM-S ophthalmic solution 15 micrograms/ml + 5 mg/ml, solution in single-dose containerCamizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64094,L64107] The European Commission approved camizestrant on July 23, 2026, Health Canada authorized it on August 4, 2026, and the FDA granted accelerated approval on September 4, 2026. … Camizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally
Synonyms: 3-pyridinamine, n-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamineFerumoxytol
go.drugbank.com/drugs/DB06215ApprovedInvestigationalFerumoxytol is an intravenously administered iron preparation previously indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) [ … [L54501] The drug remains approved in the US, with a new indication being approved in October of 2025 for Ferumoxytol's use as a diagnostic agent for MRI of the brain.
Categories: Compounds used in a research, industrial, or household settingAcetrizoic acid
go.drugbank.com/drugs/DB09347ApprovedWithdrawn[A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978. … [L1704] Acetrizoic acid presents, in the FDA records, a category of drug substance with an inactive status.[L1703]
Categories: Compounds used in a research, industrial, or household settingSmall nuclear ribonucleoprotein Sm D2
go.drugbank.com/bio_entities/BE0009119TargetHumansComponent of both the pre-catalytic spliceosome B complex and activated spliceosome C complexes (PubMed:11991638, PubMed:28076346, PubMed:28502770, PubMed:28781166). … Plays a role in pre-mRNA splicing as a core component of the spliceosomal U1, U2, U4 and U5 small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome (PubMed:11991638, PubMed:18984161
Synonyms: snRNP core protein D2Irofulven
go.drugbank.com/drugs/DB05786InvestigationalPhase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe. … MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis.
Reserpine
go.drugbank.com/drugs/DB00206ApprovedWithdrawnAn alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. … It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
Mixtures: Ser-Ap-Es, Ser-AP-ES Tab